Comparing the effect between continuous infusion and intermittent bolus of rocuronium for intraoperative neurophysiologic monitoring of neurointervention under general anesthesia

Myoung Jin Ko, MD\textsuperscript{a}, Beomjin Oh, MD\textsuperscript{b}, Jae-Wook Jung, MD\textsuperscript{b}, Dae Seok Oh, MD\textsuperscript{a}, Sung Chul Jin, MD\textsuperscript{b}, Eunsu Kang, MD\textsuperscript{a}, Yung Han Kim, MD\textsuperscript{a}, Se Hun Kim, MD\textsuperscript{a}, Hyojoong Kim, MD\textsuperscript{a,∗}

Abstract

Background: Medical researchers have been reluctant to use neuromuscular blocking drugs (NMBD) during the use of intraoperative motor evoked potential (MEP) monitoring despite the possibility of patient movement. In this study, we compared the effects of no NMBD and continuous rocuronium infusion on the incidence of patient involuntary movement and MEP monitoring.

Methods: In this study, 80 patients who underwent neuro intervention with MEP monitoring were randomly assigned into 2 groups. After an anesthetic induction, bolus of rocuronium 0.1 mg/kg was injected when it was needed (for patient involuntary movement or at the request of the surgeon) in group B, and 5 mcg/kg/min of rocuronium were infused in group I study participants. The incidence of patient involuntary movement and spontaneous respiration, the mean MEP amplitude, coefficient of variation (CV), the incidence of MEP stimulus change and train-of-four (TOF) count were compared.

Results: The incidence of involuntary movement and spontaneous movement were measured as significantly lower in group I (P < .05). The incidence of undetectable MEP did not differ as measured in both groups. The means and CVs of MEP amplitude in all limbs were significantly lower in group I. The mean TOF counts from 30 to 80 min of operation were significantly higher in group B.

Conclusion: We conclude that the continuous infusion of rocuronium effectively inhibited the involuntary movement and spontaneous respiration of the patient while enabling MEP monitoring.

Abbreviations: BIS = bispectral index, CV = coefficients of variation, IOM = intraoperative neurophysiologic monitoring, MEP = motor evoked potential, NMB = neuromuscular blockade, NMBD = neuromuscular blocking drugs, SSEP = somatosensory evoked potential, TOF = train-of-four.

Keywords: intraoperative neurophysiologic monitoring, motor evoked potential, neuromuscular blocking drug

1. Introduction

Endovascular neurointervention has grown into a good therapeutic approach to the maintenance of blood vessels and abnormalities in the central nervous system, including intracranial aneurysm, arteriovenous malformation and vascular stenosis. Most of these procedures are performed under general anesthesia, as they require limited patients movement to obtain high-resolution images and patient comfortable status. In this situation, the use of intraoperative neurophysiologic monitoring (IOM), including somatosensory evoked potential (SSEP) and motor evoked potentials (MEP) has become more common and is often considered a predictor of neurologic functional outcomes.\textsuperscript{1,2}

SSEP has been used in the discipline of neurointervention since the 1980s, but was reported to be vulnerable to detect motor damage of the patient, and the limit has been improved with the development of MEP.\textsuperscript{1,3–5} However, neuromuscular blocking drugs (NMBD) used in general anesthesia can produce muscle relaxations that are too deep to measure with the MEP. Although most institutions do not use NMBD during MEP as NMBD can disturb monitoring, some surgeons and anesthesiologists still prefer using the NMBD to maintain partial neuromuscular block.\textsuperscript{6–8} A more profound block reduces the MEP excessively and a less profound block is associated with excessive patient movement.\textsuperscript{19} In this case, when partial neuromuscular blockade is used with IOM, the goal is to minimize patient movement in order that it is not distracting or hazardous and still allow reliable MEP or electromyography recording. Achieving both of these goals requires monitoring as much as the blocking of the nerve muscles with a peripheral nerve stimulator as possible. Conventional studies have reported that patients with normal neurological function and baseline responses with sufficient amplitude, partial neuromuscular blockade with T1 reduced to 10% to 20% of baseline or train-of-four (TOF) count with 2 is acceptable.\textsuperscript{19}
There are 2 ways to give NMBD, which are by prolonged infusion and intermittent bolus injection. The bolus administration of NMBD can be performed easily on demand, but the plasma concentration of it not constant. While continuous infusion has advantage to maintaining constant plasma concentration, in general, the use of prolonged infusion of NMBD with moderate to high elimination half-life was limited due to the delayed recovery due to accumulation. But it is noted that rocuronium has similar recovery index (the time required for the first twitch of TOF to recovery from 25% to 75% of baseline) between bolus and 2h infusion. So, rocuronium seems to be suitable for prolonged infusion. However, research is lacking on which of the above 2 methods can help achieve a smoother operation without disturbing MEP measurements. Therefore, it is noted in this study, which compares the effect of prolonged infusion and bolus injection of rocuronium on the progress of neurointervention and MEP monitoring.

2. Methods

This study was approved by the Institutional Review Board of the Haenundae Paik Hospital and registered at https://cris.nih.go.kr (protocol number KCT0002829). All patients signed an informed consent. This prospective randomized study has proceeded between December 2017 and April 2018. Total 80 patients who were undergoing elective coil embolization or stent insertion under general anesthesia with MEP monitoring after diagnosis of cerebral aneurysm in our hospital were enrolled in this study. The patients were excluded if they had an American Society of Anesthesiologists physical status IV or higher, severe cardiopulmonary disorders with hemodynamic instability, significant hepatic disease, end-stage renal disease, neuromuscular disease or motor neuron disease.

We randomly assigned the patients into 1 of 2 groups and administered rocuronium intravenously either continuous infusion (Group I, 40 patients) or intermittent bolus manner (Group B, 40 patients). The blocked randomization was performed by using computer software generation. In this context, only the attending anesthesiologist was informed about the study group before administering the anesthesia. The patients entered the operation room without premedication. The use of an electrocardiography, pulse oxymetry, capnography, noninvasive blood pressure and bispectral index (BIS) were monitored intra-operatively. In this case, the neuromuscular transmission module (Intellivue NMT, Philips, USA) was adjusted to monitor degree of muscle relaxation. An arterial catheter was also placed in all of the patients for the direct measurement of blood pressure after an anesthetic induction.

Anesthesia was induced by intravenous propofol (effect-site concentration 2–5 μg/ml, Schneider model) with remifentanil (effect-site concentration 2–4 ng/ml, Minto model) through a target-controlled infusion pump (Orchestra, Fresenius kabi, USA). After the induction, a tracheal intubation was facilitated with rocuronium (0.6 mg/kg). Remifentanil was titrated to control the change of blood pressure to the surgical procedure within a 20% range of its preoperative value, if blood pressure raised or fell more than 10% of the preoperative value, the target concentration was raised or lowered. And propofol was infused at a dose range of 2 to 4 mcg/ml to maintain BIS between 40 and 60. In this case, phenylephrine was infused intravenously when hypotension occurred. It is noted that hypotension was defined as a decrease in the mean arterial pressure of more than 20% of preoperative baseline, or below 60 mmHg.

Twenty minutes after induction, the patients in group I were administered rocuronium infusion by 5 mcg/kg/min. Likewise the patients in group B were injected rocuronium 0.1 mg/kg as needed. The bolus rocuronium administration was needed when spontaneous breathing or movement was detected, or when the surgeon requested such action or procedure.

The response of the adductor pollicis brevis muscle to the TOF stimulation of the ulnar nerve was monitored every 5 min. At that time, the MEP amplitude was measured by a neurophysiologist who was blinded to the study group. MEP was recorded by paired subdermal needle electrodes inserted into all four limb muscles (abductor pollicis brevis, vastus lateralis, extensor hallucis longus and abductor hallucis). The MEPs were triggered by an electrical stimulation of the scalp with Nim-eclipse system IOM machine (Medtronic, USA). It delivered electrical stimulus pulse trains (pulse width = 50 ms, n = 5, interpulse interval = 2 ms, 500Hz) between the 2 electrodes placed over the motor cortex region at C3 and C4 (International 10–20 System). The optimal amplitude was obtained by adjusting the MEP stimulus intensity in intervals of 50 to 100 V from a starting value of 400 V, and a change of stimulus intensity was recorded. The MEP was checked through every insertion of each coil, or when the surgeon decided and the amplitudes of MEP or change of stimulus intensity were recorded by neurophysiologist. To estimate within the patient variability, we compared the mean MEP amplitudes and the coefficients of variation (CVs, %) of all measured MEP amplitudes in four limbs between groups. When the MEP alteration occurred, such as a loss of MEP or a sudden decrease of MEP amplitude by more than 50%, the neurophysiologist recorded that measurement as an undetectable MEP.

After the surgery, propofol, remifentanil, and/or rocuronium were discontinued. At a TOF count 2 or more, a single bolus dose of sugammadex 2mg/kg was administered, and at a TOF count less than 2, sugammadex 4mg/kg was administered. When the patient’s status reached consciousness and spontaneous respiration were restored, at that time the endotracheal tube was removed.

In this study, our primary outcomes were incidence of spontaneous respiration, involuntary movement and amplitude of MEP. The spontaneous respiration was noted by attending anesthesiologist when curare cleft of capnography was appeared and the involuntary movement was noted by attending neurosurgeon. Patient movements included acceptable movement (movement that not excessive and not interrupt the surgery including mild cough), unacceptable movement (movement that interrupt surgery including head or limbs elevation) and no movement. In these terms, we also recorded total dose of anesthetics, phencylphrine, sugammadex during surgery, TOF, and emergence time (defined as a time interval between the discontinuation of anesthetics and a tracheal extubation).

2.1. Statistical analysis

We determined that the sample size for this study following a pilot study. Our primary outcome was the involuntary movement difference between both groups, and there was a 10% difference in a pilot study. We expected that there would be a 10% difference of involuntary movement between group B and group I. It is particularly important that a power analysis ($\alpha = 0.05$, $\beta = 0.20$) showed that a total 70.640 patients would be required, as well as considering 10% of dropouts, we thus enrolled 80 patients in the study. The data are presented for the frequency with a noted percentage for the categorical variables and mean ±
Shapiro-Wilk test was employed for test of normality assumption. Perioperative clinical data.

The patient’s demographic variables.

|        | Group I (n = 39) | Group B (n = 40) | P value |
|--------|-----------------|-----------------|---------|
| Sex    |                 |                 |         |
| male   | 12 (30.8)       | 9 (22.5)        | .41     |
| female | 27 (69.2)       | 31 (77.5)       |         |
| Age (years) | 58.9 ± 9.8     | 62.0 ± 9.3      | .15     |
| Weight (kg) | 63.7 ± 9.2      | 62.2 ± 11.0     | .28     |
| Height (cm) | 161.0 ± 8.0   | 158.4 ± 7.1     | .13     |
| BMI (kg/m²) | 24.6 ± 3.2       | 24.7 ± 5.0      | .78     |
| ASA    |                 |                 |         |
| 1      | 15 (38.5)       | 13 (32.5)       | .86     |
| 2      | 22 (56.4)       | 25 (62.5)       |         |
| 3      | 2 (5.1)         | 2 (5.0)         |         |

ASA = American society of anesthesiologists classification; BMI = body mass index.

1 P values were derived from chi-square test.
2 P values were derived from Mann-Whitney U test.
3 P values were derived from Fisher exact test.
Shapiro-Wilk test was employed for test of normality assumption.

3. Results

We enrolled a total 80 patients in this study, and 1 patient in group I was dropped because of the malfunction of MEP monitoring device. The patient’s demographic data are presented in Table 1. In fact, the variables in Table 1 showed no considerable differences as reviewed. The perioperative clinical data are shown in Table 2. The mean anesthesia time and operation time did not differ between the 2 groups. It is noted that the mean propofol and remifentanil doses did not differ between the 2 groups, but the total administered rocuronium doses are significantly higher in infusion group. Because of this, it is noted that higher doses of sugammadex were needed to reverse neuromuscular blockade in group I, and time of emergence from anesthesia did not differ. The overall incidence of hypotension and total amount of administered phenylephrine doses were not different between the 2 groups.

Table 3 shows the MEP parameters. The mean stimulus intensity was not different between the 2 groups. The incidences of changing stimulus intensity were 4 in each group. Both mean MEP amplitudes and CVs of all limbs were significantly smaller in group I. The undetectable MEP were noted to have occurred in 3 patients in group I and 5 patients in group B, but it did not show significant difference as measured. There was no spontaneous respiration of patients as noted and exhibited in group I, whereas 6 cases were occurred in group B (P = .26). The incidence of involuntary movement of patients was also significantly lower in group I (P = .006).

Figure 1 shows mean TOF counts checked every 10 min in both groups. The TOF counts were significantly higher in group B from 30 min. In group B, the TOF counts were maintained between 1 and 2.

The unacceptable movement that can interrupt the process of neuromonitoring did not occur in group I, whereas it was noted to have occurred during 4 cases in group B. Broadly speaking, it could not show significant difference (P = .116).

When we separated the procedures into long and short duration of procedure based on 60 min, the incidence of involuntary movement in long duration procedure was significantly high in group B (Table 4).

No patient showed significant a MEP change during the procedures, and no motor deficit was found postoperatively in all patients.

| Table 1 | The patient’s demographic variables. |
|---------|--------------------------------------|
|         | Group I (n = 39) | Group B (n = 40) | P value |
| Sex     |                 |                 |         |
| male    | 12 (30.8)       | 9 (22.5)        | .41     |
| female  | 27 (69.2)       | 31 (77.5)       |         |
| Age (years) | 58.9 ± 9.8     | 62.0 ± 9.3      | .15     |
| Weight (kg) | 63.7 ± 9.2      | 62.2 ± 11.0     | .28     |
| Height (cm) | 161.0 ± 8.0   | 158.4 ± 7.1     | .13     |
| BMI (kg/m²) | 24.6 ± 3.2       | 24.7 ± 5.0      | .78     |
| ASA     |                 |                 |         |
| 1       | 15 (38.5)       | 13 (32.5)       | .86     |
| 2       | 22 (56.4)       | 25 (62.5)       |         |
| 3       | 2 (5.1)         | 2 (5.0)         |         |

ASA = American society of anesthesiologists classification; BMI = body mass index.

1 P values were derived from chi-square test.
2 P values were derived from Mann-Whitney U test.
3 P values were derived from Fisher exact test.
Shapiro-Wilk test was employed for test of normality assumption.

| Table 2 | Perioperative clinical data. |
|---------|-----------------------------|
|         | Group I (n = 39) | Group B (n = 40) | P value |
| Anesthesia time (min) | 95.4 ± 19.8     | 88.9 ± 18.4     | .08     |
| Operation time (min)  | 62.5 ± 17.1     | 56.7 ± 18.8     | .01     |
| Emergence time (min)  | 12.1 ± 3.6      | 11.6 ± 3.3      | .49     |
| Total infused propofol (mg) | 603.1 ± 173.4 | 527.2 ± 117.9 | .09     |
| Total infused remifentanil (mcg) | 553.9 ± 171.3 | 500.5 ± 193.9 | .11     |
| Incidence of hypotension |               |                 |         |
| Yes      | 27 (69.2)       | 28 (70.0)       | .94     |
| No       | 12 (30.8)       | 12 (30.0)       |         |
| Total injected phenylephrine (mcg) | 742.45 ± 1768.2 | 1092.8 ± 1742.9 | .73     |
| Total injected rocuronium (mg) | 54.5 ± 13.6   | 39.7 ± 7.6      | < .001  |
| Total injected sugammadex (mg) | 169.8 ± 71.0   | 122.5 ± 27.9    | .006    |

1 P values were derived from Mann-Whitney U test.
2 P values were derived from chi-square test.
Shapiro-Wilk test was employed for test of normality assumption.

| Table 3 | Comparisons of MEP variables. |
|---------|--------------------------------|
|         | Group I (n = 39) | Group B (n = 40) | P value |
| Mean stimulus intensity (V) | 406.8 ± 22.1 | 403.7 ± 32.7 | .51     |
| Mean MEP amplitude (mV)     | 1483.9 ± 1213.5 | 2608.0 ± 1646.2 | < .001 |
| Right Arm                    | 1383.1 ± 1219.9 | 2783.2 ± 2059.9 | < .001 |
| Left Arm                     | 780.3 ± 571.8   | 1502.2 ± 1182.7 | .007    |
| Right Leg                    | 1050.1 ± 1063.1 | 1521.8 ± 1235.9 | .03     |
| CV of MEP amplitude (mV)     | 73.1 ± 22.9      | 53.3 ± 26.8      | .001    |
| Right Arm                    | 30.0 ± 23.1      | 55.3 ± 20.8      | < .001  |
| Left Arm                     | 35.4 ± 21.7      | 51.6 ± 28.6      | .01     |
| Right Leg                    | 39.5 ± 24.4      | 54.4 ± 33.8      | .03     |
| Increase of stimulus intensity |               |                 |         |
| Yes                              | 4 (10.3)       | 3 (7.5)         | .71     |
| No                               | 35 (89.7)      | 37 (92.5)       |         |
| Decrease of stimulus intensity   | 0 (0.0)        | 1 (2.5)         | .009    |
| Yes                              | 39 (100.0)     | 39 (97.5)       |         |
| Incidence of spontaneous respiration |            |                 |         |
| Yes                              | 0 (0.0)        | 6 (15.0)        | .03     |
| No                               | 39 (100.0)     | 34 (85.0)       |         |
| Incidence of involuntary movement |             |                 |         |
| Yes                              | 2 (5.1)        | 12 (30)         | .006    |
| No                               | 37 (94.9)      | 28 (70)         |         |
| Incidence of undetectable MEP   | 3 (7.7)        | 5 (12.5)        | .71     |
| Yes                              | 36 (92.3)      | 35 (87.5)       |         |

CV = coefficient of variation; MEP = motor evoked potential.
1 P values were derived from Mann-Whitney U test.
2 P values were derived from Fisher exact test.
3 P values were derived from chi-square test.
Shapiro-Wilk test was employed for test of normality assumption.
4. Discussion

Intraoperative neurophysiologic monitoring is widely used for brain or spine surgery to detect complications early. Especially, the MEP monitoring is used as a supplementary technique to detect perforating vessel compromise, which may lead to motor impairment not detected by SSEP.[14]

Intraoperative MEP is usually characteristic of a recording of compound muscle action potential of peripheral muscle (eg, abductor pollicis brevis muscle, tibialis anterior muscle) in a patient, and it requires the transmission of a neural signal through the neuromuscular junction. In other words, the use of NMBD during surgery can significantly affect the amplitude of MEP and raise inter-trial variability of MEP amplitudes.[15,16] In line with this data, the amplitude of MEP is decreasing with increasing neuromuscular blockade (NMB), and is not able to be detected from more profound NMB. Likewise, it is important to note that in reviewing the complexity of using NMBD, Sloan advised avoiding NMBD during MEP monitoring.[17] By the same token in this case, Kothbauer also worried that a partial NMB could add an uncontrolled variable to this measurement when interpreting the available MEP data, and this factor can worsen the specificity of MEP in a patient.[18] In these terms, no NMB during surgery is related to problems such as a limited exposure of surgical field and involuntary patient movement.[6–8] Patient movement during the MEP monitoring may interfere with surgery and raise serious safety concerns.[19] Hemmer et al reported that 3.2% of the patients with no NMB exhibited unacceptable movement during craniotomy for aneurysm clipping.[20] Some studies that reported that the incidence of spontaneous movement did not differ between partial and no NMB groups.[12,21] It is noted that in our study, the incidence of involuntary movement and spontaneous respiration were significantly lower in the infusion group.

In the observance of ‘no NMBD use methods’ for preventing unexpected movement, more anesthetics may be needed in that case, and it can cause unwanted deep anesthesia in the patient. One consequence of this is that deep anesthesia is associated with some problem such as hypotension, shock and delayed emergence. Although the relation between anesthetic depth and long-term survival is inconclusive, many literature reviews suggest an association between deep anesthesia and poorer outcomes.[22–24] Leslie and Short recommend maintaining optimal anesthetic depth; and it is defined as deep enough to avoid intraoperative responsiveness and postoperative recall, but light enough to avoid intraoperative hypotension and postoperative side effect in the patient.[25] In present study, we titrated anesthetics to keep BIS values between 40 and 60, and administered a low amount of NMBD to prevent involuntary patient movement. To keep the BIS values consistent, the target concentrations of anesthetics might be lower and the incidence of

| Variable                  | Long duration of operation | Short duration of operation |
|---------------------------|----------------------------|-----------------------------|
|                           | Group I (n = 23)       | Group B (n = 16)               | Group I (n = 16)       | Group B (n = 24)               |
| Incidence of involuntary movement | yes | 2 (8.7) | 6 (37.5) | 0 (0) | 3 (12.5) | .045 | .26 |
|                           | no  | 21 (91.3) | 10 (62.5) | 16 (100) | 21 (87.5) |
| Incidence of unacceptable movement | yes | 0 (0) | 3 (18.8) | 0 (0) | 1 (4.2) | .06 | 1.00 |
|                           | no  | 23 (100) | 13 (81.3) | 16 (100) | 23 (95.8) |

Long: over 60 min; short: less than 60 min. 

P values were derived from Fisher exact test.
patient movement seemed to be higher than previous studies, but additional trials are needed to support this conclusion.

In previous studies, an excessive movement was observed in 6% to 10% of the patients undergoing MEP monitoring without NMB.\(^{[29-26]}\) We have also shown that in about 10% of patients in group B, an involuntary movement was recorded. However, the degree of movement was not considered in former studies. In another study, the intraoperative movement during MEP was classified as either no incision induced movement (defined as “coughing” or reflexive limb movement temporally elicited by MEP stimulation), or excessive field movement (defined as grossly visible head movement as determined by surgical and anesthesia team), and the incidences were measured as 1% and 2.2%, respectively.\(^{[20]}\) In these terms, those studies did not classify the movement from the point of view of a surgeon. This brings us to understand that we classified the patient movements into unacceptable and acceptable movement, as noted according to the degree of disturbing the procedure. When rocuronium is administered in repeated dosages, its serum profiles show a sawtooth pattern. So, when the plasma concentration of rocuronium is high, the patient movement can be suppressed, but when that is low, not only does the patient movement occur more, but it can be more severe enough to interfere the surgery. On the other hand, when the plasma concentration is kept constant by continuous infusion of rocuronium, even if patient movement occurs, it is expected the occurrence of unacceptable movement would be suppressed. And in this study, although the difference did not show statistical significance, no unacceptable movement was reported in group I, whereas 4 were reported in group B. This was equivalent to 5%, and the small dose of NMBD was injected to resume the operations for the study at that time. Some researchers showed that the elimination half-life of rocuronium administered as a bolus followed by continuous infusion was not significantly different with elimination half-life of single bolus dose of rocuronium.\(^{[27,28]}\) But there is lack of data describing the pharmacokinetics of intermittently injected rocuronium.

The prevailing discipline for successful MEP monitoring includes the procedure to first, proper waveform and amplitude, which are needed. In the meantime, because the propound NMB includes the procedure to inhibit the involuntary movement and spontaneous respiration of the patient, without disturbing the MEP monitoring. Additionally, it was noted that the MEP variability was more favorable when rocuronium was continuously infused.

**Author contributions**

**Conceptualization:** Myoung Jin Ko, Hyojoong Kim.

**Data curation:** Beomjin Oh, Jae-Wook Jung, Dae Seok Oh, Eunsu Kang.

**Investigation:** Myoung Jin Ko, Jae-Wook Jung, Dae Seok Oh, Sung Chul Jin, Yong Han Kim, Se Hun Kim.

**Methodology:** Myoung Jin Ko, Sung Chul Jin, Se Hun Kim.

**Supervision:** Yong Han Kim, Hyojoong Kim.

**Visualization:** Eunsu Kang.

**Writing – original draft:** Hyojoong Kim.

**Writing – review & editing:** Myoung Jin Ko, Hyojoong Kim.

**References**

[1] Deletis V. What does intraoperative monitoring of motor evoked potentials bring to the neurosurgeon? Acta Neurochir 2005;147:1015–7.

[2] Martinez Pinoe A, Cubells C, Garcia P, et al. Implementation of intraoperative neurophysiological monitoring during endovascular procedures in the central nervous system. Interv Neurul 2015;3:85–100.

[3] Hacke W. Desmedt JE. Evoked potentials monitoring in interventional neuroradiology. Neumonitigiting in surgery Elsevier, Amsterdam:1989;331–42.

[4] Jones SJ, Buonamassa S, Crookdar HA. Two cases of quadriaparesis following anterior cervical discectomy, with normal perioperative somatosensory evoked potentials. J Neurol Neurosurg Psychiatry 2003;74:273–6.

[5] Seelenyi A, Deletis V. Motor evoked potentials. J Neurosurg 2004;101:563–4.
[6] Mendiratta A, Emerson RG. Neurophysiologic intraoperative monitoring of scoliosis surgery. J Clin Neurophysiol 2009;26:62-9.
[7] Kalkman CJ, Drummond JC, Kennedy NA, et al. Intraoperative monitoring of tibialis anterior muscle motor evoked responses to transcranial electrical stimulation during partial neuromuscular blockade. Anesth Analg 1992;75:584-9.
[8] Sloan TB, Heyer EJ. Anesthesia for intraoperative neurophysiologic monitoring of the spinal cord. J Clin Neurophysiol 2002;19:430-43.
[9] Sloan TB. Muscle relaxant use during intraoperative neurophysiologic monitoring. J Clin Monit Comput 2013;27:35-46.
[10] Jellish WS, Brody M, Sawicki K, et al. Recovery from neuromuscular blockade after either bolus and prolonged infusions of cisatracurium or rocuronium using either isoflurane or propofol-based anesthetics. Anesth Analg 2000;91:1230-5.
[11] American Clinical Neurophysiology Society. Guideline 8: Guidelines for recording clinical EEG on digital media. J Clin Neurophysiol 2006;23:122-4.
[12] Kim WH, Lee JJ, Lee SM, et al. Comparison of motor-evoked potentials monitoring in response to transcranial electrical stimulation in subjects undergoing neurosurgery with partial vs no neuromuscular block. Br J Anaesth 2013;110:567-76.
[13] Chung YH, Chung IS, Kim MH, et al. Comparing the effects of vecuronium and cisatracurium on electrophysiologic monitoring during neurosurgery: A randomized controlled study. Anesth Pain Med 2017;12:213-9.
[14] Neuloh G, Schramm J. Monitoring of motor evoked potentials compared with somatosensory evoked potential monitoring during nitrous oxide anesthesia from the tibialis anterior muscle after transcranial electrical stimulation. Anesth Analg 1998;88:457-70.
[15] Woodforth IJ, Hicks RG, Crawford MR, et al. Variability of motor-evoked potentials recorded during nitrous oxide anesthesia from the tibialis anterior muscle after transcranial electrical stimulation. Anesth Analgesia 1996;82:744-9.
[16] Sloan TB. Anesthesia management and intraoperative electrophysiologic monitoring. In: Monitoring the nervous system for anesthesiologists and other health care professionals. Springer; 2017:317-341.
[17] Kothbauer K. Intraoperative neurophysiologic monitoring for intramedullary spinal-cord tumor surgery. Neurophysiol Clin 2007;37:407-14.
[18] MacDonald DB. Safety of intraoperative transcranial electrical stimulation motor evoked potential monitoring. J Clin Neurophysiol 2002;19:416-29.
[19] Hemmer LB, Zerri C, Bebawy JF, et al. The incidence of unacceptable movement with motor evoked potentials during craniotomy for aneurysm clipping. World Neurosurg 2014;81:99-104.
[20] Kim S, Jin S, Karm M, et al. Comparison of false-negative/positive results of intraoperative evoked potential monitoring between no and partial neuromuscular blockade in patients receiving propofol/remifentanil-based anesthesia during cerebral aneurysm clipping surgery: a retrospective analysis of 685 patients. Medicine 2016;95:
[21] Monk TG, Saini V, Weldon BC, et al. Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg 2005;100:4-10.
[22] Leslie K, Myles PS, Forbes A, et al. The effect of bispectral index monitoring on long-term survival in the B-aware trial. Anesth Analg 2010;110:816-22.
[23] Short TG, Leslie K, Campbell D, et al. A pilot study for a prospective, randomized, double-blind trial of the influence of anesthetic depth on long-term outcome. Anesth Analg 2014;118:981-6.
[24] Leslie K, Short TG. Anesthetic depth and long-term survival: an update. Can J Anaesth 2016;63:233-40.
[25] Szelenyi A, Kothbauer K, De Camargo AB, et al. Motor evoked potential monitoring during cerebral aneurysm surgery: Technical aspects and comparison of transcranial and direct cortical stimulation. Operative Neurosurgery 2005;57(suppl 4):331-8.
[26] Harris W, Breton JG, et al. Threshold-level “multipulse transcranial electrical stimulation of motor cortex for intraoperative monitoring of spinal motor tracts: Description of method and comparison to somatosensory evoked potential monitoring. J Neurosurg 1998;88:457-70.
[27] Scofield M, McCullough GC, et al. Pharmacokinetics of rocuronium following continuous infusion in patients undergoing aneurysm clipping. J Neurosurg Anesthesiol 2011;23:64.
[28] McCoy EP, Mirakhar RK, Maddineni VR, et al. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anesthesia. Br J Anaesth 1996;76:29-33.
[29] Guo L, Gelb AW. False negatives, muscle relaxants, and motor-evoked potentials. J Neurosurg Anesthesiol 2011;23:64.
[30] Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007;104:575-81.